SGK Provides Massive Support for Children with Leukemia: 7.4 Billion TL Financed

In the realm of healthcare services provided under Turkey's social security umbrella, a critical financial milestone has been reached in the fight against leukemia, the most common childhood cancer. According to an official statement by the Social Security Institution (SGK), a total resource of 7.431 billion TL was transferred during the first seven months of 2024 to facilitate access to healthcare for children with leukemia. This vast budget covers a wide spectrum, from diagnostic tests and analysis processes to modern drug treatments, medical device support, and hospital inpatient expenses. According to the institution's data, 4.209 billion TL of this expenditure was allocated directly to diagnostic and treatment expenses, 3.204 billion TL to vital medications, and 18 million TL to the procurement of necessary medical devices.

This move by SGK is not just a budget allocation; it is also supported by the inclusion of 112 different drugs used in leukemia treatment, which are often very costly, in the reimbursement list. Emphasizing that it stands by families at every stage of the treatment process, the institution aims to ensure that children with leukemia can access the most modern medical facilities without any additional fees. The financing provided in this context is considered one of the most concrete reflections of Turkey's 'social state' principle in the field of health. In particular, the coverage of high-cost and long-term processes such as chemotherapy, radiotherapy, and bone marrow transplantation under SGK's guarantee prevents thousands of families from facing economic ruin during this challenging period.

Background of the Development

Turkey's social security system, with the structural reforms it has undergone in the last twenty years, has created a comprehensive protective shield for oncology patients, especially children. In the past, while families of children treated for leukemia experienced serious difficulties due to expensive drugs that had to be brought from abroad and high hospital costs, SGK's continuous updating of reimbursement lists has radically changed this picture. In the institutional background, the process of integrating the latest treatment protocols into the system has been accelerated through regulations made via the Health Implementation Communiqué (SUT). This process has ensured that not only drug procurement but also advanced diagnostic methods such as genetic tests and molecular analysis are included in the scope of public financing.

The fact that a large portion of the drugs used in leukemia treatment are high-tech and imported makes SGK's determination to keep these drugs on the reimbursement list even more significant, despite fluctuations in exchange rates. Thanks to strategic agreements with pharmaceutical companies and its bulk purchasing power, the institution can offer even the most expensive oncology drugs to its citizens free of charge. This recent figure of 7.4 billion TL proves how critical the share of oncology has become within SGK's health expenditures and that the priority given to child health has become an institutional policy.

From a historical perspective, Turkey's general health insurance system offers broader coverage for chronic and severe diseases like leukemia compared to many developed countries in the world. The fact that 112 drugs are on the reimbursement list includes not only standard chemotherapy drugs but also targeted smart drugs and immunotherapy options. This situation plays a key role in Turkey's treatment success rates reaching international standards and even exceeding these standards in some areas.

Expert and Industry Insights

Healthcare sector representatives and oncology experts state that these figures announced by SGK provide a vital guarantee at the point of access to treatment. Experts remind that leukemia treatment does not only consist of medication but also requires continuous monitoring, infection control, and supportive treatments, stating that the 4.2 billion TL diagnostic and treatment budget supports this holistic approach. According to industry stakeholders, this financial support provided by SGK is of critical importance in five key points:

• Financial Accessibility: The ability of families to access even the most expensive treatments without out-of-pocket spending increases treatment compliance and the chance of success.
• Drug Diversity: Having 112 different drugs under reimbursement allows doctors to choose the most appropriate and personalized treatment protocol for each patient.
• Technological Infrastructure: The budget allocated for diagnostic tests encourages the widespread use of the latest diagnostic technologies in public hospitals and contracted institutions.
• Medical Device Support: The 18 million TL medical device financing facilitates patients' access to the equipment they need during home care processes.
• Sustainability: The state's allocation of such a high budget to oncology demonstrates the capacity of the health system to protect priority groups even in times of crisis.

Oncology experts draw attention to the importance of early diagnosis and uninterrupted treatment, especially in childhood leukemias, and emphasize that this financial comfort provided by SGK strengthens the hands of physicians. Drugs being on the reimbursement list means fewer bureaucratic obstacles and a shorter time for patients to access medication. This situation reduces the risk of disease recurrence while positively affecting survival rates.

Economic and Social Implications

From a macroeconomic perspective, this 7.4 billion TL investment by SGK is a social transfer that protects the most vulnerable segments of society. This model, which eliminates the devastating effect of health expenditures on the household budget, contributes to the protection of social welfare by preventing the impoverishment of families. Socially, it reinforces the perception that the state stands by its citizens in their most difficult days and strengthens the sense of social solidarity. The psychological stress experienced by families in long-term treatments like leukemia is alleviated to some extent by the elimination of financial concerns.

Economically, these expenditures also create a significant market volume for the local pharmaceutical industry and healthcare providers. SGK's presence in the market as a major buyer plays a decisive role in balancing drug prices and standardizing the quality of healthcare services. These planned expenditures, made to keep the burden on public finances at manageable levels, are seen as an investment in raising a healthy generation in the long run. Every child treated is brought back to the economy and society as a productive individual of the future.

Furthermore, as a social reflection of these supports, the burden on patient associations and non-governmental organizations is also decreasing. Instead of covering basic treatment costs, NGOs can allocate more resources to the psychosocial support processes of patients and activities that increase the quality of life. This allows the health ecosystem in Turkey to work more efficiently and coordinately.

Future Projections and Outlook

In the coming period, SGK's support in the field of oncology is expected to continue increasing. Especially with the development of gene therapies and personalized medicine applications, it is predicted that the costs of next-generation drugs to be included in the reimbursement list will rise even further. In this context, SGK's strategy of including these innovative treatments in the system while maintaining budget discipline will form the cornerstone of Turkey's health vision. Thanks to the institution's digitalization steps and drug tracking systems, it is aimed to use resources more efficiently and prevent abuses.

In future projections, the share of preventive health services and early diagnosis screenings within the budget is also expected to increase. New support packages for the post-treatment rehabilitation processes and social adaptation of children with leukemia are on the agenda. Official authorities signal that the number of drugs, currently 112, will continue to be updated in line with scientific data and clinical needs. This situation also supports Turkey's goal of becoming a regional health hub in the field of oncology.

In conclusion, this massive expenditure of 7.4 billion TL carried out in the first seven months of 2024 has once again confirmed Turkey's commitment to sustainability and social justice in health. In a global environment where risks and costs are increasing, the continuation of the treatment of children with leukemia in an uninterrupted and free manner is successfully fulfilled as one of the most fundamental duties of the state. In the upcoming calendar, these figures are expected to reach record levels by the end of the year with the inclusion of new treatment protocols into the system.